MedTrace Logo

Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy

NCT00500552 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2010-11-04

No results posted yet for this study

Summary

Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many patients experience symptoms of breathlessness, fatigue and chest pain. These symptoms are not always controlled with current therapies.

Recently the investigators showed that a drug called Perhexiline markedly improved exercise capacity and symptoms in patients with heart failure. In this proposal the investigators wish to test whether Perhexiline improves exercise capacity and relieves symptoms in patients with HCM

Conditions

Interventions

DRUG

Perhexiline/Placebo

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • University College London Hospitals

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University Hospital Birmingham

    lead OTHER

Principal Investigators

  • Michael Frenneaux, MD · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00500552 on ClinicalTrials.gov